Bright Peak Therapeutics AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bright Peak Therapeutics AG
Private Company Edition: Nine new venture capital mega-rounds include Insilico’s series C, $250m from Blackstone for a CAR-T therapy spinout from Intellia and a $210m series B round for Umoja.
Building on 20 years of work and positive preclinical data, and backed by a fresh injection of cash, Alentis is taking its liver fibrosis candidate into Phase I trials in the fourth quarter.